News stories about Tenax Therapeutics (NASDAQ:TENX) have been trending somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a news impact score of 0.10 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 42.1146055652415 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Tenax Therapeutics (NASDAQ:TENX) traded down $0.02 during midday trading on Wednesday, reaching $0.44. 354,900 shares of the company’s stock were exchanged, compared to its average volume of 215,533. The company has a market cap of $12.57, a P/E ratio of -0.33 and a beta of 1.86. Tenax Therapeutics has a 52-week low of $0.31 and a 52-week high of $2.65.
TRADEMARK VIOLATION NOTICE: This news story was reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/10/tenax-therapeutics-tenx-receives-daily-coverage-optimism-score-of-0-10.html.
Tenax Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.